Concepedia

Lingli Zhang

LZ

Statistics

Publications

3

Citations

39

H-Index

3

Active since

2024

Affiliations

Nanjing Medical University(Current)

Fujian Medical University

Fujian Provincial Cancer Hospital

China Pharmaceutical University

Lingli Zhang is an author at Nanjing Medical University specializing in willingness-to-pay thresholds, pharmacoeconomic modeling, and low-density lipoprotein cholesterol reduction.

ORCID

Publications per year

2024–2025

3

Publications

3

Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China

Jingxuan Wei, Kai Xu, Yingtao Lin et al. · International Journal of Clinical Pharmacy · 2024 · 15 citations

, , +15

Patient versus physician preferences for lipid‐lowering drug therapy: A discrete choice experiment

Lingli Zhang, Jiali Chen, Zhaoliu Cao et al. · Health Expectations · 2024 · 13 citations · Full text

, , +17

Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis

Kai Xu, Man Yu, Qingli Sun et al. · Annals of Medicine · 2025 · 11 citations · Full text

, , +17

1–3 of 3